Jiangsu Hengrui Medicine Co., Ltd

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1970-01-01

Employees: -

Market Cap: $38.9B

Website: http://www.hrs.com.cn/english/

Clinical Trials

A Study of Food Effect on the Pharmacokinetics of Fuzuloparib Capsules in Chinese Healthy Adult Subjects

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: Fuzuloparib

First Posted Date: 2022-06-30

Last Posted Date: 2022-09-08

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 20

Registration Number: NCT05440006

Locations: 🇨🇳
Wannan Medical College Yijishan Hospital, Wuhu, Anhui, China

A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

Phase 3

Recruiting

Conditions: HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

Interventions: Drug: SHR-A1811
Drug: Pyrotinib in combination with Capecitabine.

First Posted Date: 2022-06-21

Last Posted Date: 2022-08-10

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 269

Registration Number: NCT05424835

Locations: 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China

A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer

Phase 2

Conditions: Advanced Esophageal Cancer

Interventions: Drug: HR070803

First Posted Date: 2022-06-21

Last Posted Date: 2022-09-06

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT05425472

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Study on the Pharmacokinetic Effect of Itraconazole on SHR0302 Tablets in Healthy Subjects

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: itraconazole、 SHR0302 tablets

First Posted Date: 2022-06-03

Last Posted Date: 2022-12-22

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 14

Registration Number: NCT05404724

Locations: 🇨🇳
The Third Hospital of Changsha, Changsha, Hunan, China

A Trial of SHR0410 Injection in Postsurgical Pain Management

Phase 2

Conditions: Postsurgical Pain

Interventions: Drug: SHR0410 Injection
Drug: Placebo for SHR0410 Injection

First Posted Date: 2022-05-27

Last Posted Date: 2022-08-22

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 108

Registration Number: NCT05394402

Locations: 🇨🇳
Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China

A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy Volunteers

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: SHR0302 Tablets
Drug: Midazolam Maleate Tablets
Drug: Warfarin Sodium Tablets
Drug: Omeprazole Enteric Capsules
Drug: Vitamin K1 Tablets
Drug: Repaglinide Tablets

First Posted Date: 2022-05-26

Last Posted Date: 2022-12-22

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT05392127

Locations: 🇨🇳
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China

A Study of SHR8554 Injection for the Treatment of Pain After Orthopedic Surgery

Phase 2

Completed

Conditions: Pain

Interventions: Drug: SHR8554 Injection
Drug: Morphine
Drug: Saline Solution

First Posted Date: 2022-05-16

Last Posted Date: 2023-12-26

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 320

Registration Number: NCT05375305

Locations: 🇨🇳
Shanghai Jiaotong University School of Medicine,Renji Hospital, Shanghai, Shanghai, China

Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers

Phase 1

Completed

Conditions: Hypercholesterolemia and Hyperlipidemia

Interventions: Drug: SHR-1209

First Posted Date: 2022-05-12

Last Posted Date: 2023-01-12

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 159

Registration Number: NCT05370950

Locations: 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Phase 2

Active, not recruiting

Conditions: Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Interventions: Drug: Camrelizumab
Drug: Camrelizumab、Rivoceranib

First Posted Date: 2022-05-10

Last Posted Date: 2023-08-22

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 251

Registration Number: NCT05367687

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma

Phase 1

Recruiting

Conditions: Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma

Interventions: Drug: HRS-3738

First Posted Date: 2022-05-06

Last Posted Date: 2022-07-29

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 198

Registration Number: NCT05363800

Locations: 🇨🇳
Zhejiang University School of Medicine The First Affiliated Hospital, Hangzhou, Zhejiang, China
🇨🇳
Henan cancer Hospital, Zhengzhou, Henan, China
🇨🇳
Sheng Jing Hospital of China Medical University, Shengyang, Liaoning, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy